Advertisement

Cardiovascular Disease Posttransplant

  • Phuong-Thu T. Pham
    Correspondence
    Address reprint requests to Phuong-Thu T. Pham, MD, Department of Medicine, Division of Nephrology, Kidney and Pancreas Transplantation, David Geffen School of Medicine at UCLA, 200 UCLA Medical Plaza, Suite 365C1, Los Angeles, CA 90095.
    Affiliations
    Division of Nephrology, Kidney and Pancreas Transplantation, Department of Medicine, University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA.
    Search for articles by this author
  • Phuong-Chi T. Pham
    Affiliations
    Division of Nephrology, Kidney and Pancreas Transplantation, Department of Medicine, University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA.

    Olive View-University of California Los Angeles Medical Center, Sylmar, CA.
    Search for articles by this author
  • Gabriel M. Danovitch
    Affiliations
    Division of Nephrology, Kidney and Pancreas Transplantation, Department of Medicine, University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA.
    Search for articles by this author

      Summary

      Renal transplantation is currently the preferred treatment modality for virtually all suitable candidates with end-stage renal disease. Compared with dialysis, kidney transplantation improves both patient survival and quality of life. Nonetheless, posttransplant cardiac complications are associated with increased morbidity and mortality after renal transplantation. When compared with the general population, cardiovascular mortality in transplant recipients is increased by nearly 10-fold among patients within the age range of 35 and 44 and at least doubled among those between the ages of 55 and 64. Although renal transplantation ameliorates cardiovascular disease risk factors by restoring renal function, it introduces new cardiovascular risks derived, in part, from immunosuppressive medications. We provide an overview of the literature on conventional and unconventional cardiovascular disease risk factors after renal transplantation, and discuss an approach to their medical management.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Seminars in Nephrology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Meier-Kriesche H.U.
        • Schold J.D.
        • Kaplan B.
        Preservation of long-term renal allograft survival: a challenge for the years to come.
        Am J Transplant. 2005; 5: 632-633
        • Anavekar N.S.
        • McMurray J.J.
        • Velazquez E.J.
        • et al.
        Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction.
        N Engl J Med. 2004; 31: 1285-1295
        • Simmons E.M.
        • Langone A.
        • Sezer M.T.
        Effect of renal transplantation on biomarkers of inflammation and oxidative stress in end-stage renal disease patients.
        Transplantation. 2005; 79: 914-919
        • Ducloux D.
        • Kazory A.
        • Chalopin J.M.
        Predicting coronary heart disease in renal transplant recipients.
        Kidney Int. 2004; 66: 441-447
        • Ojo A.O.
        Cardiovascular complications after renal transplantation and their prevention.
        Transplantation. 2006; 82: 603-611
        • Kalil R.S.
        • Hudson S.L.
        • Gaston R.S.
        Determinants of cardiovascular mortality after renal transplantation: a role for cytomegalovirus?.
        Am J Transplant. 2003; 3: 79-81
        • Humar A.
        • Gillingham K.
        • Payne W.D.
        • et al.
        Increased incidence of cardiac complications in kidney transplant recipients with cytomegalovirus disease.
        Transplantation. 2000; 70: 310-313
        • Kasiske B.L.
        • Anjum S.
        • Shah R.
        • et al.
        Hypertension after transplantation.
        Am J Kidney Dis. 2004; 43: 1071-1081
        • Premasathian N.C.
        • Muehrer R.
        • Brazy P.C.
        • et al.
        Blood pressure control in kidney transplantation.
        J Hum Hypertens. 2004; 18: 871-877
        • Opelz G.
        • Wujciak T.
        • Ritz E.
        • et al.
        Association of chronic kidney graft failure with recipient blood pressure.
        Kidney Int. 1998; 53: 217-222
        • Kreis H.
        • Oberbauer R.
        • Campistol J.M.
        Long-term benefits with sirolimus-based therapy after early cyclosporine withdrawal.
        J Am Soc Nephrol. 2004; 15: 809-817
        • Pascual J.
        • Van Hooff J.P.
        • Salmela K.
        Three-year observational follow-up of a multicenter, randomized trial on tacrolimus-based therapy with withdrawal of steroids or mycophenolate mofetil after renal transplantation.
        Transplantation. 2006; 85: 55-61
        • Kasiske B.L.
        • Chakkera H.A.
        • Roel J.
        Explained and unexplained ischemic heart disease risk after renal transplantation.
        J Am Soc Nephrol. 2000; 11: 1735-1743
        • Brenner B.M.
        • Cooper M.E.
        • de Zeeuw D.
        • et al.
        Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.
        N Engl J Med. 2001; 345: 861-869
        • Agodoa L.Y.
        • Appel L.
        • Bakris G.L.
        • et al.
        Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial.
        JAMA. 2001; 285: 2719-2728
        • Wright Jr, J.T.
        • Bakris G.
        • Greene T.
        • et al.
        Effect of blood pressure lowering and antihypertensive kidney disease: results from the AASK trial.
        JAMA. 2002; 288: 2421-2431
        • De Champlain
        • Karas M.
        • Nguyen P.
        • et al.
        Different effects of nifedipine and amlodipine on circulating catecholamines levels in essential hypertensive patients.
        J Hypertens. 1998; 16: 1357-1369
        • Pham P.T.
        • Danovitch G.M.
        • Pham P.C.
        • et al.
        The medical management of the renal transplant recipient.
        in: Johnson R.J. John Feehally Comprehensive clinical nephrology. 3rd ed. Mosby, Philadelphia2007: 1848-1853
        • Kasiske B.L.
        • Snyder J.J.
        • Gilbertson D.
        • et al.
        Diabetes mellitus after kidney transplantation in the United States.
        Am J Transplant. 2003; 3: 178-185
        • Teutonico A.
        • Schena P.F.
        • Di Paolo S.
        Glucose metabolism in renal transplant recipients: effect of calcineurin inhibitor withdrawal and conversion to sirolimus.
        J Am Soc Nephrol. 2005; 16: 3128-3135
        • Zhang N.
        • Su D.
        • Qu S.
        • et al.
        Sirolimus is associated with reduced islet engraftment and impaired beta-cell function in transplants.
        Diabetes. 2006; 55: 2429-2436
        • Jindal R.M.
        • Hjelmesaeth J.
        Impact and management of posttransplant diabetes mellitus.
        Transplantation. 2000; 70: SS58-SS63
        • Cheng A.Y.Y.
        • Fantus I.G.
        Oral antihyperglycemic therapy for type 2 diabetes mellitus.
        CMAJ. 2005; 172: 213-226
        • Hatorp V.
        • Hansen K.T.
        • Thomsen M.S.
        Influence of drugs interacting with CYP3A4 on the pharmacokinetics, pharmacodynamics and safety of the prandial glucose regulator repaglinide.
        J Clin Pharmacol. 2003; 43: 649-660
        • Niemi M.
        • Backman J.T.
        • Neuvonen P.J.
        • et al.
        Rifampin decreases the plasma concentrations and effects of repaglinide.
        Clin Pharmacol Ther. 2000; 68: 495-500
        • Collins R.
        • Peto R.
        • Armitage J.
        • Heart Protection Collaborative Group
        Heart Protection Study of cholesterol-lowering with simvastatin in 20, 536 high-risk individuals: a randomized-placebo controlled trial.
        Lancet. 2002; 360: 7-22
        • Messerli A.W.
        • Aronow H.D.
        • Sprecker D.L.
        The Lescol Intervention Prevention Study (LIPS): start all patients on statin early after PCI.
        Cleve Clin J Med. 2003; 70: 561-566
        • Holdaas H.
        • Fellstrom B.
        • Jardine A.G.
        • et al.
        Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicenter, randomised, placebo-controlled trial.
        Lancet. 2003; 361: 2024-2031
        • Holdaas H.
        • Fellstrom B.
        • Jardine A.G.
        • et al.
        Beneficial effect of early initiation of lipid-lowering therapy following renal transplantation.
        Nephrol Dial Transplant. 2005; 20: 974-980
        • Fellstrom B.
        • Holdaas H.
        • Jardine A.G.
        • et al.
        Effect of fluvastatin end points in the Assessment of Lescol in renal Transplantation (ALERT) trial.
        Kidney Int. 2004; 66: 1549-1555
        • Masterson R.
        • Hewitson T.
        • Leikis M.
        • et al.
        Impact of statin treatment on 1-year functional and histologic renal allograft outcome.
        Transplantation. 2005; 80: 332-338
        • Ballantyne C.M.
        • Corsini A.
        • Davidson M.H.
        • et al.
        Risk for myopathy with statin therapy in high-risk patients.
        Arch Intern Med. 2003; 163: 553-564
        • Murdoch D.
        • Scott L.J.
        Ezetimibe/Simvastatin: a review of its use in the management of hypercholesterolemia.
        Am J Cardiovasc Drugs. 2004; 4: 405-422
        • Puthenparumpil J.J.
        • Keough-Ryan T.
        • Kiberd M.
        • et al.
        Treatment of hypercholesterolemia with ezetimibe in the kidney transplant population.
        Transplant Proc. 2005; 37: 1033-1035
        • Canzanello V.J.
        • Schwartz L.
        • Tater S.J.
        • et al.
        Evolution of cardiovascular risk after liver transplantation: a comparison of cyclosporine A and tacrolimus FK(506).
        Liver Transpl Surg. 1997; 3: 1-9
        • Evehart J.E.
        • Lonardero M.
        • Lake J.R.
        • et al.
        Weight change and obesity after liver transplantation: incidence and risk factors.
        Liver Transpl Surg. 1998; 4: 285-296
        • Alexander J.W.
        • Goodman H.R.
        • Gervin K.
        • et al.
        Gastric bypass in morbidly obese patients with chronic renal failure and kidney transplant.
        Transplantation. 2004; 78: 469-474
        • Ducloux D.
        • Motte G.
        • Challier B.
        • et al.
        Serum total homocysteine and cardiovascular disease occurrence in chronic, stable renal transplant recipients: a prospective study.
        J Am Soc Nephrol. 2000; 11: 134-137
        • Marcucci R.
        • Zanazzi M.
        • Bertoni E.
        • et al.
        Vitamin supplementation reduces the progression of atherosclerosis in hyperhomocysteinemic renal transplant recipients.
        Transplantation. 2003; 9: 1551-1555
        • Cheng K.S.
        • Mikhailidis D.P.
        • Hamilton G.
        • et al.
        A review of the carotid and femoral intima media thickness as an indicator of the presence of peripheral vascular disease and cardiovascular risk factors.
        Cardiovasc Res. 2002; 4: 528-538
        • Winkelmayer W.C.
        • Kramar R.
        • Curhan G.C.
        • et al.
        Fasting plasma total homocysteine levels and mortality and allograft loss in kidney transplant recipients: a prospective study.
        J Am Soc Nephrol. 2005; 16: 255-260
        • Bonaa K.H.
        • Njolstad I.
        • Ucland P.M.
        • et al.
        Homocysteine lowering and cardiovascular event after acute myocardial infarction.
        N Engl J Med. 2006; 354: 1578-1588
        • Ducloux D.
        • Kazory A.
        • Chapolin J.M.
        Predicting coronary heart disease in renal transplant recipients: a prospective study.
        Kidney Int. 2004; 66: 441-447
        • Winkelmayer W.C.
        • Lorenz M.
        • Kramar R.
        • et al.
        C-reactive protein and body mass index independently predict mortality in kidney transplant recipients.
        Am J Transplant. 2004; 4: 1148-1154
        • Hansson G.K.
        Inflammation, atherosclerosis, and coronary artery disease.
        N Engl J Med. 2005; 352: 1685-1695
        • Grotz W.
        • Siebig S.
        • Olschewski M.
        • et al.
        Low-dose aspirin therapy is associated with improved allograft function and prolonged allograft survival after kidney transplantation.
        Transplantation. 2004; 77 (1848-183)
        • Lopez-Gomez J.M.
        • Perez-Flores I.
        • Jofre R.
        • et al.
        Presence of a failed kidney transplant in patients who are on hemodialysis is associated with chronic inflammatory state and erythropoietin resistance.
        J Am Soc Nephrol. 2004; 1: 2494-2501
        • Peddi V.R.
        • Dean D.E.
        • Hariharam S.
        • et al.
        Proteinuria following renal transplantation: crrelation with histopathology and outcome.
        Transplant Proc. 1997; 29: 101-103
        • Fernandez-Fresnedo G.
        • Escallada R.
        • Rodrigo E.
        • et al.
        The risk of cardiovascular disease associated with proteinuria in renal transplant patients.
        Transplantation. 2002; 73: 1345-1348
        • Roodnat J.I.
        • Mulder P.G.
        • Rischen-Vos J.
        • et al.
        Proteinuria after renal transplantation affects not only graft survival but also patient survival.
        Transplantation. 2001; 72: 438-444
        • Lim H.S.
        • Blann A.D.
        • Chong A.Y.
        • et al.
        Plasma vascular endothelial growth factor, angiopoietin-1, angiopoeitin-2 in diabetes: implications for cardiovascular risk and effects of multifactorial interventions.
        Diabetes Care. 2004; 27: 2918-2924
        • van den Akker J.M.
        • Wetzels J.F.
        • Hoitsma A.J.
        Proteinuria following conversion from azathioprine to sirolimus in renal transplant recipiients.
        Kidney Int. 2006; 70: 1355-1357
        • Afzali B.
        • Al-Khoury S.
        • Shah N.
        • et al.
        Anemia after renal transplantation.
        Am J Kidney Dis. 2006; 48: 519-536
        • Turkowski-Duhem A.
        • Kamar N.
        • Cointault O.
        • et al.
        Predictive factors of anemia within the first year post renal transplant.
        Transplantation. 2005; 80: 903-909
        • Augustine J.J.
        • Schulak J.A.
        • Bodziak K.A.
        • et al.
        Comparative effects of sirolimus and mycophenolate mofetil on erythropoiesis in kidney transplant patients.
        Am J Transplant. 2004; 4: 2001-2006
        • Jaster R.
        • Bittorf T.
        • Klinken S.P.
        • et al.
        Inhibition of proliferation but not erythroid differentiation of j2E cells by rapamycin.
        Biochem Pharmacol. 1996; 51: 1181-1185
        • Djamali A.
        • Becker Y.T.
        • Simmons W.D.
        • et al.
        Increasing hematocrit reduces early posttransplant cardiovascular risk in diabetic transplant recipients.
        Transplantation. 2003; 76: 816-820
        • Imoagene-Oyedeji A.E.
        • Rosas S.E.
        • Doyle A.M.
        • et al.
        Posttransplantation anemia at 12 months in kidney recipients treated with mycophenolate mofetil: risk factors and implications for mortality.
        J Am Soc Nephrol. 2006; 17: 3240-3247
        • Winkelmayer W.C.
        • Lorenz M.
        • Kramar R.
        • et al.
        Percentage of hypochromic red blood cells is an independent risk factor for mortality in kidney transplant recipients.
        Am J Transplant. 2004; 4: 2075-2081
        • Ishitani M.B.
        • Milliner D.S.
        • Kim D.Y.
        • et al.
        Early subclinical coronary artery calcification in young adults who were pediatric kidney transplant recipients.
        Am J Transplant. 2005; 5: 1689-1693
        • Rosas S.E.
        • Mensah K.
        • Weinstein R.B.
        • et al.
        Coronary artery calcification in renal transplant recipients.
        Am J Transplant. 2005; 5: 1942-1947
        • Litwin M.
        • Wuhl E.
        • Jourdan C.
        • et al.
        Altered morphologic properties of large arteries in children with chronic renal failure and after renal transplantation.
        J Am Soc Nephrol. 2005; 16: 1494-1500
        • Hernandez D.
        • Rufino M.
        • Bartolomei S.
        • et al.
        Clinical impact of preexisting vascular calcifications on mortality after renal transplantation.
        Kidney Int. 2005; 67: 2015-2020
        • Heinze G.
        • Mitterbauer C.
        • Regele H.
        • et al.
        Angiotensin-converting enzyme inhibitor or angiotensin II type 1 receptor antagonist therapy is associated with prolonged patient and graft survival after renal transplantation.
        J Am Soc Nephrol. 2006; 17: 889-899
        • Opelz G.
        • Zeier M.
        • Laux G.
        • et al.
        No improvement of patient or graft survival in transplant recipients treated with angiotensin-converting enzyme inhibitors or angiotensin II type 1 receptor blockers: a collaborative transplant study report.
        J Am Soc Nephrol. 2006; 17: 3257-3262